about
Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis preventionThe omega-3 fatty acid docosahexaenoic acid favorably modulates the inflammatory pathways and macrophage polarization within aorta of LDLR(-/-) mice.Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α-linolenic acids; bioactivities and potential use as biomarkers.Insight into the contribution of isoprostanoids to the health effects of omega 3 PUFAs.Simultaneous quantitative profiling of 20 isoprostanoids from omega-3 and omega-6 polyunsaturated fatty acids by LC-MS/MS in various biological samples.Lipid peroxidation and antioxidant status in rat: effect of food restriction and wheel running.Quantification of 4-hydroxy-2-nonenal-protein adducts in the in vivo gastric digesta of mini-pigs using a GC-MS/MS method with accuracy profile validation.DHA at nutritional doses restores insulin sensitivity in skeletal muscle by preventing lipotoxicity and inflammation.Pulmonary arterial systolic pressure and susceptibility to high altitude pulmonary edemaNeuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the inflammatory response of human macrophagesBioavailability and antioxidant capacity of plant extracts rich in polyphenols, given as a single acute dose, in sheep made highly susceptible to lipoperoxidationPreservation of micronutrients during rapeseed oil refining: a tool to optimize the health value of edible vegetable oils? Rationale and design of the Optim'Oils randomized clinical trialOptimized rapeseed oil enriched with healthy micronutrients: a relevant nutritional approach to prevent cardiovascular diseases. Results of the Optim'Oils randomized intervention trialMuscle Loss Associated Changes of Oxylipin Signatures During Biological Aging: An Exploratory Study From the PROOF CohortIncreasing intake of long-chain n-3 PUFA enhances lipoperoxidation and modulates hepatic gene expression in a dose-dependent manner
P50
Q27320935-78EE6C64-BD1B-48F2-BC6E-01951FAC2B83Q34232750-50800BA5-24BA-48BD-BF79-0E1A21ADA881Q38281110-8E1CA9A4-5146-4644-8E5D-68C0C3AA5674Q39370378-9113A9F2-5FBF-4CF0-8787-428AA3166379Q41062855-62F58693-ACC6-4BD2-B1C7-5EDD091EED94Q45944912-D01F9B40-B2E9-456F-BD69-15AC5B44C6F6Q51640549-B445CF70-E0F7-46E8-BD73-0F9A8D02838DQ55058413-8E60F4A8-9373-4D19-888C-8259533842B8Q57099712-BDD945C8-1EC0-45EB-9452-0AE0793841D4Q57244033-90A5B482-0A56-46EB-9C8C-43C72CF6AA43Q80255357-8E281F25-FA0C-4388-B1A4-2EFBC57A84A9Q82442571-7E331EA6-A5AB-47EA-981F-53CBE2B3BC49Q84563418-1ACA4874-E68A-4F97-A6E6-2A2277070F03Q91100450-6D9A3D6C-C099-445E-B8FB-A05EAEA14B53Q95386194-6C6A1BCE-A022-4057-B06E-38BDF8473F92
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Cécile Gladine
@en
Cécile Gladine
@nl
type
label
Cécile Gladine
@en
Cécile Gladine
@nl
prefLabel
Cécile Gladine
@en
Cécile Gladine
@nl
P31
P496
0000-0001-7693-6241